AN2 Therapeutics Inc. (ANTX) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, ANTX scores 46 out of 100, a letter grade of D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC of -35% and FCF yield of -16.86%), Whale 13F Flow at 13/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 12/20 (beta 1.0 and sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5, Piotroski F 3/9, Debt/Equity 0.5). Per the same rating, the cash-generation and insider-conviction pillars are the weakest, meaning the business is consuming rather than producing cash and insider activity offers little support. The strongest pillar, institutional flow, is still only moderate. For a prospective investor, the implication is that valuation support must come from future clinical or commercial outcomes rather than current operating economics, which carries elevated risk of further dilution or drawdown if those outcomes slip.

AN2 Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the Profile section. The source data does not identify its products, customers, or revenue model. The FY 2023–FY 2025 financials report revenue of $0.0M in each period, per the SEC financials section, so the company is not currently generating reported revenue. Not available in source data for further business detail.

Per the SEC financials, losses narrowed from $-64.7M net income in FY 2023 to $-35.2M in FY 2025, while reported cash declined from $21.4M to $19.9M. Per the market data section, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with Debt/Equity of 0.5. Per the financials, debt is not reported, so the Debt/Equity figure cannot be reconciled against the reported debt line.

Per the recent news section, six items are dated within roughly the prior 15 hours of the data timestamp. Catalysts include a Yahoo Finance UK and TradingView item covering market action, a Stock Titan item discussing a planned study with clearance in three countries and an estimated 155,000 U.S. patients with the targeted blood cancer, a Business Wire item on inducement grants under Listing Rule 5635(c)(4), a Stock Titan item on a director receiving 2,283 shares instead of cash, and a Business Wire item on upcoming investor conferences. Every item carries a YELLOW light and MARKET WIRE impact label. Risk watch items include the inducement grants and the director share-in-lieu-of-cash arrangement, both of which are routine compensation mechanics but still relate to equity issuance. Per the Butterfly Supply-Chain Graph, no proprietary signals are listed.

• What products or clinical programs generate ANTX's value, and what is the timeline to revenue given reported revenue of $0.0M across three periods?
• What is the reported debt balance, given that debt is listed as N/A for every period while Debt/Equity is cited at 0.5?
• What is the cash runway implied by $19.9M in cash against FY 2025 FCF of $-29.8M, and what financing has been or may be required?
• What are the specific holders, insider transactions, and analyst estimates behind the RQD whale and insider pillar scores?
• What are the terms and dilution impact of the inducement grants and share-in-lieu-of-cash arrangements referenced in recent news?